Seres Therapeutics, a company focused on microbiome therapeutics, is working to develop a unique class of biological drugs for the modulation of the colonic microbiome. The company's lead candidate, SER-109, has already completed Phase III clinical trials for the treatment of recurrent Clostridioides difficile infection. SER-155, an oral fermented microbiome therapeutic, is currently in Phase 1b clinical trials, while SER-287 and SER-301 are in Phase 2b and Phase 1b, respectively, to treat ulcerative colitis. The company has also established license agreements with NHSc Rx License GmbH, Société des Produits Nestlé and AstraZeneca Inc. for the development of therapeutic products based on microbiome technology. Seres Therapeutics, formerly known as Seres Health, was incorporated in 2010 and is based in Cambridge, Massachusetts.
Seres Therapeutics's ticker is MCRB
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Seres Therapeutics
It is serestherapeutics.com
Seres Therapeutics is in the Healthcare sector
Seres Therapeutics is in the Biotechnology industry
The following five companies are Seres Therapeutics's industry peers: